Innovations in Deep Vein Thrombosis (DVT): A Look at the Future

Innovations in Deep Vein Thrombosis (DVT): A Look at the Future

**Disclaimer:** This blog post is intended for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.

Introduction

Deep Vein Thrombosis (DVT) represents a significant global health concern, characterized by the formation of blood clots in deep veins, most commonly in the legs. If left untreated, DVT can lead to severe complications, including pulmonary embolism (PE), a potentially fatal condition where a clot travels to the lungs. Beyond acute risks, DVT can also result in long-term morbidity such as Post-Thrombotic Syndrome (PTS), which significantly impairs patients' quality of life [1, 56]. The economic burden associated with DVT management is substantial, driven by recurrent hospitalizations, prolonged anticoagulation, and the treatment of chronic sequelae [7].

In recent decades, advancements in medical science have profoundly reshaped the landscape of DVT diagnosis, treatment, and prevention. From novel pharmacological agents to sophisticated interventional techniques and the burgeoning application of artificial intelligence, the future of DVT management is poised for transformative change. This article delves into these cutting-edge innovations, offering an academic perspective on how they are revolutionizing patient care and outlining the future directions in the fight against DVT.

Evolving Diagnostic Landscape

The accurate and timely diagnosis of DVT is paramount for effective management and prevention of complications. While traditional diagnostic methods have served as cornerstones, ongoing research and technological advancements are introducing more precise and personalized diagnostic tools.

Beyond D-dimer: Novel Biomarkers

The D-dimer test has long been a crucial component of DVT diagnostic pathways, primarily due to its high negative predictive value, making it effective in ruling out DVT in low-risk patients. However, its utility is often limited by poor specificity, leading to false-positive results in conditions such as advanced age, cancer, or inflammation, which frequently necessitate unnecessary imaging [11]. This inherent limitation has spurred an intensive search for novel biomarkers that can offer superior diagnostic discrimination by more accurately reflecting the specific pathophysiology of VTE.

Recent investigations have identified several promising candidate molecules. E-selectin and P-selectin, adhesion molecules integral to thrombus formation and inflammation, have shown potential as diagnostic markers with potentially higher specificity than D-dimer [12]. While some studies have yielded mixed results regarding their prognostic value, particularly in predicting short-term mortality in acute symptomatic PE [13], further research, especially in the context of cancer-associated thrombosis (CAT), is ongoing [14]. The Khorana score, a widely used risk assessment model for CAT, also faces limitations due to low sensitivity and specificity, further complicated by often elevated baseline D-dimer levels in cancer patients [15, 67].

High-throughput proteomic and metabolomic screens are also revealing entirely new molecular candidates and enhancing our understanding of thrombus pathophysiology [16]. A 2024 study, for instance, utilized metabolomic profiling to identify a distinct metabolic signature in the red blood cells of patients with acute VTE, with specific metabolites like adenosine 3′,5′-diphosphate, glutathione, and adenine demonstrating exceptionally high diagnostic performance [18]. These multi-omics approaches hold significant promise for identifying highly accurate, early diagnostic markers, though rigorous clinical validation in large prospective trials is still required [19].

Advanced Imaging Techniques

Imaging modalities are undergoing a significant transformation, moving towards enhanced resolution and reduced patient exposure. Photon-Counting CT (PCCT) represents a fundamental shift in CT image acquisition, directly converting X-ray photon energies into electrical signals. This technology offers improved spatial resolution, reduced beam artifacts, and superior iodine signal in vessels, allowing for clearer visualization of fine anatomical details and better discrimination of small pulmonary vessel opacification. Crucially, PCCT can achieve significant radiation dose reduction (up to 50%) while improving image quality and reducing contrast media, benefiting patients with renal impairment [21, 22, 23].

Artificial intelligence (AI), particularly machine learning (ML) and deep learning algorithms, is emerging as a transformative tool in VTE diagnosis and management [24]. AI-assisted ultrasound and CT angiography (CTA) analysis, including FDA-cleared algorithms for detecting incidental PE on CTPA, have demonstrated high specificity and sensitivity [24, 25]. AI can function as a second reader for radiologists, automatically detecting PE and incidental PE, thereby reducing missed or delayed diagnoses and improving diagnostic accuracy. Beyond image analysis, AI is being leveraged to optimize clinical workflows and care coordination by flagging suspected PE and incidental PE, triggering alerts to multidisciplinary response teams, and prioritizing urgent cases. This can lead to more timely management, with AI-assisted reprioritization reducing report turnaround times and cutting median detection times for incidental PE from days to just over 2 hours [26]. Despite its broad potential, challenges remain in AI integration, including the need for large, diverse datasets, addressing inter-reader variability, data privacy concerns, and ethical considerations [26].

Novel Pharmacological Therapies

Anticoagulants remain the cornerstone of DVT treatment and prevention, yet current limitations include incomplete thrombus resolution, VTE recurrence, and bleeding risks [27]. Recent research has focused on refining existing therapies and exploring groundbreaking new agents.

Refining DOACs in Special Populations

Direct Oral Anticoagulants (DOACs) have largely replaced Vitamin K Antagonists (VKAs) as first-line treatment for most VTE patients due to their convenience, effectiveness, and favorable safety profiles [29]. However, their optimal use in specific patient populations continues to be an active area of investigation.

For patients with Cancer-Associated Thrombosis (CAT), the choice of anticoagulant is particularly complex, given that CAT accounts for 30% of VTE cases [30]. Guidelines increasingly support DOACs, with recent trials demonstrating their effectiveness in reducing CAT recurrence comparable to Low Molecular Weight Heparins (LMWHs) [31, 32]. A 2024 meta-analysis, differentiating between individual DOACs, revealed distinct safety profiles, with apixaban showing a reduced risk of recurrence and lower major bleeding risk compared to other DOACs and parenteral anticoagulants [30]. Current guidelines still favor LMWH in patients at high risk of bleeding, oral drug malabsorption, or significant drug-drug interactions [33]. The API-CAT trial further demonstrated that a reduced-dose apixaban regimen was non-inferior in preventing recurrent VTE in CAT patients who had completed at least 6 months of anticoagulation, with a lower rate of major bleeding [34].

Anticoagulant therapy in patients with severe chronic kidney disease (CKD) or end-stage renal disease (ESRD) on dialysis presents a significant challenge due to the increased risk of both thrombosis and bleeding, and the renal clearance of many anticoagulants [35]. While these patients were often excluded from initial DOAC trials, a 2024 meta-analysis found that DOACs, particularly apixaban, were associated with a significantly reduced risk of major bleeding and mortality compared to VKAs in CKD patients, providing reassurance for their use in this high-risk group [36, 37].

In elderly patients, concerns about the risk-benefit profile of newer treatments have led to hesitancy in employing advanced therapies. Real-world data from the GARFIELD-VTE registry indicate that clinicians often opt for reduced-dose DOACs for extended secondary prophylaxis [39, 40]. While these lower doses appear to maintain similar VTE recurrence rates, they are associated with higher bleeding rates, likely due to the frailty and comorbidities inherent in this population [38]. A recent meta-analysis supported apixaban due to its preferential bleeding risk profile in older adults [41].

During pregnancy and the postpartum period, VTE occurs in approximately 1–2 out of every 1000 women, necessitating careful management to reduce maternal and fetal morbidity and mortality [42, 43]. LMWH remains the anticoagulant of choice due to its established safety profile and inability to cross the placental barrier. VKAs and DOACs are generally avoided during pregnancy due to potential adverse fetal effects, and DOACs are not recommended during breastfeeding due to insufficient data on infant safety [42, 43].

The Next Therapeutic Frontier: Factor XI(a) Inhibitors

The ultimate goal of anticoagulant research is to develop agents that effectively prevent thrombosis without compromising physiological hemostasis, thereby minimizing bleeding risk. Factor XI (FXI) has emerged as a prime target for this purpose, as it plays a crucial role in thrombus amplification and stabilization within the intrinsic coagulation pathway, but has a modest role in hemostasis [44, 45, 46].

Abelacimab, a long-acting, fully human monoclonal antibody that inhibits FXI, has shown promising results. A phase 2 trial demonstrated that a single post-operative intravenous dose of abelacimab significantly reduced VTE rates by approximately 80% after total knee arthroplasty, with no observed bleeding [47]. The AZALEA-TIMI 71 phase 2 trial, comparing once-monthly subcutaneous abelacimab to rivaroxaban for stroke prevention in atrial fibrillation, was terminated early due to a greater-than-expected reduction in clinical bleeding, with the 150 mg dose reducing major or clinically relevant non-major bleeding by 67% and major bleeding alone by 74% [49]. These findings suggest that FXI(a) inhibitors could represent a significant paradigm shift in anticoagulation management, offering a more favorable bleeding risk profile. Phase 3 trials are currently underway to evaluate abelacimab for CAT, a population that could greatly benefit from an anticoagulant with reduced bleeding risk [27].

Other novel pharmacotherapies in development include antagonists of fibrinolysis inhibitors, such as α2-antiplasmin and thrombin-activatable fibrinolysis inhibitors. These agents aim to enhance natural clot-dissolving mechanisms without significantly increasing bleeding risk [27, 50, 51, 52].

Advancements in Interventional Management

Interventional approaches for acute VTE are rapidly evolving, offering new options for patients who may not respond adequately to anticoagulation alone or who are at high risk of severe complications.

Catheter-Based Interventions for PE and DVT

The management of intermediate-risk PE often involves a delicate balance between the risk of hemodynamic deterioration and the bleeding risks associated with systemic thrombolysis. Catheter-based therapies have emerged as a potential solution, and recent randomized trials are providing crucial evidence to guide their use [53].

The PEERLESS trial, the first large-scale randomized trial comparing large-bore mechanical thrombectomy (LBMT) with the FlowTriever system to catheter-directed thrombolysis (CDT), demonstrated that LBMT was superior to CDT. This superiority was driven by significant reductions in post-procedural ICU utilization and fewer episodes of clinical deterioration, suggesting that faster, more complete thrombus removal leads to more rapid clinical improvement and lower resource utilization [54]. The ongoing HI-PEITHO trial is further addressing the question of whether to intervene at all in intermediate-high-risk PE patients by comparing ultrasound-assisted, catheter-directed thrombolysis (USCDT) plus standard anticoagulation versus anticoagulation alone [55].

For DVT, interventional goals primarily focus on reducing the long-term burden of Post-Thrombotic Syndrome (PTS), a debilitating condition characterized by pain, swelling, and skin changes [56]. While earlier trials like ATTRACT and CAVA did not demonstrate a significant reduction in overall PTS incidence with CDT for most patients [57], subgroup analyses of the ATTRACT trial suggested that patients with extensive iliofemoral DVT might benefit from a greater reduction in moderate-severe PTS [58]. Consequently, guidelines recommend CDT for patients with extensive iliofemoral DVT, particularly those with phlegmasia cerulea dolens, and for younger patients with low bleeding risk where reducing PTS severity is a key therapeutic goal [58].

Advances in mechanical thrombectomy devices continue to provide a range of options for removing organized thrombus from the venous system. Devices like the ClotTriever, VenaCore, and FlowTriever offer unique design features optimized for different types of thrombus and venous anatomies [59, 60]. The ClotTriever device, for instance, has revolutionized the treatment of acute and subacute DVTs by enabling the extraction of wall-adherent clot, reducing the need for thrombolytics, shortening hospital stays, and minimizing ICU admissions [37, 43]. The VenaCore device further addresses challenging venous occlusions, particularly long-standing ones, by engaging and removing fibrotic material [69, 71].

Advances in VTE Prevention and Risk Stratification

The paradigm for VTE prevention and risk stratification is shifting from a one-size-fits-all approach to more dynamic and personalized prediction methods, aiming to better identify high-risk patients for prophylaxis and spare low-risk individuals from unnecessary treatment.

Traditional risk assessment models (RAMs) like the IMPROVE and Padua scores for hospitalized medical patients and the Khorana score for ambulatory cancer patients have limitations. A 2025 study comparing six RAMs in cancer patients found that all displayed poor to modest predictive performance, partly due to inadequate capture of VTE risk associated with cancer treatments [61, 62, 63]. Another challenge lies in balancing VTE risk against bleeding risk, as anticoagulant thromboprophylaxis, while effective, increases bleeding risk and healthcare costs. The development of validated bleeding RAMs, such as the Cleveland Clinic Bleeding Model, is crucial for a more comprehensive assessment [64].

Researchers are increasingly turning to machine learning (ML) models for more precise and targeted de-escalation strategies. Despite challenges like class imbalance due to the low incidence of VTE, a 2024 study successfully developed an ML model that achieved higher specificity and equivalent sensitivity compared to the traditional Padua score by modeling a “fuzzy population” of patients with similar risk profiles but different outcomes [65]. This highlights the vast potential of ML to generate robust, precise, and clinically meaningful risk prediction tools. Furthermore, personalized prevention strategies also aim to spare low-risk individuals from unnecessary treatment. The 2024 TriP(cast) trial, for example, used a score to safely identify patients with lower limb trauma who did not require preventive anticoagulants, thereby reducing burden, cost, and potential harm [66]. The future of VTE prevention likely involves a two-step assessment, combining scoring systems to exclude low-risk patients with more personalized assessments integrating specific risk factors like bleeding risk to guide decision-making.

Future Directions and Unmet Needs

The future of DVT management is characterized by a move towards personalized patient care, integrating novel diagnostic technologies, advanced therapeutics, and evidence-based interventions. This transition promises more reliable diagnoses, safer treatments, and improved outcomes.

Generating personalized VTE prevention and treatment will require the integration of comprehensive risk models that combine genomic, proteomic, and metabolomic data with dynamic clinical variables and AI-enhanced imaging. This will enable clinicians to generate real-time, accurate risk profiles for both thrombosis and bleeding, facilitating personalized thromboprophylaxis [3]. The emergence of factor XI(a) inhibitors also holds significant promise for improved safety profiles, provided they demonstrate comparable efficacy to current first-line anticoagulants [27].

In the interventional space, future efforts will focus on delineating patient populations that would most benefit from endovascular treatments and selecting appropriate modalities. High-quality data from trials like PEERLESS and the forthcoming HI-PEITHO will lead to improved evidence-based pathways for managing intermediate-risk acute PE. Within a decade, AI-powered triage and integrated risk assessment within multidisciplinary VTE response teams may further refine the rapid selection of the most appropriate therapy for each patient.

Despite these advancements, several unmet needs persist. These include optimizing the prevention and treatment of chronic VTE sequelae, such as PTS and chronic thromboembolic pulmonary hypertension, as acute therapies have had limited impact on these long-term complications. High-quality evidence is also needed to guide VTE management in special populations often excluded from major trials, including patients with severe obesity, severe renal or hepatic failure, and during pregnancy. Finally, the challenge of clinical translation remains paramount, ensuring that new diagnostics and therapeutics are integrated equitably, efficiently, and accurately into clinical practice.

Conclusion

The landscape of Deep Vein Thrombosis management is undergoing a profound transformation, driven by relentless innovation in diagnostics, pharmacology, and interventional therapies. From the precision offered by novel biomarkers and AI-enhanced imaging to the promise of safer anticoagulants like Factor XI(a) inhibitors and advanced mechanical thrombectomy devices, the future holds immense potential for improving patient outcomes. While challenges remain, particularly in personalizing care for diverse populations and addressing chronic complications, the trajectory of innovation points towards a future where DVT is managed with greater precision, efficacy, and patient-centered care. INVAMED is committed to contributing to these advancements, ensuring that healthcare professionals and patients alike have access to the most effective solutions in the fight against DVT.

References

• [1] Kearon C., Akl E.A., Ornelas J., Blaivas A., Jimenez D., Bounameaux H., Huisman M., King C.S., Morris T.A., Sood N., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–352. doi: 10.1016/j.chest.2015.11.026. [DOI] [PubMed] [Google Scholar]
• [3] Wendelboe A.M., Weitz J.I. Global health burden of venous thromboembolism. Arterioscler. Thromb. Vasc. Biol. 2024;44:1007–1011. doi: 10.1161/ATVBAHA.124.320151. [DOI] [PubMed] [Google Scholar]
• [7] Grosse S.D., Nelson R.E., Nyarko K.A., Richardson L.C., Raskob G.E. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb. Res. 2016;137:3–10. doi: 10.1016/j.thromres.2015.11.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [11] Linkins L.A., Bates S.M., Lang E., Kahn S.R., Douketis J.D., Julian J., Parpia S., Gross P., Weitz J.I., Spencer F.A., et al. Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis. Ann. Intern. Med. 2013;158:93–100. doi: 10.7326/0003-4819-158-2-201301150-00003. [DOI] [PubMed] [Google Scholar]
• [12] Yadav R., Kumari K., Joshi R., Verma K., Paliwal S., Dwivedi J., Sharma S. P-selectin and E-selectin: Key macromolecules in thrombus formation and resolution. Int. J. Biol. Macromol. 2025;13:145259. doi: 10.1016/j.ijbiomac.2025.145259. [DOI] [PubMed] [Google Scholar]
• [13] Oblitas C.M., Galeano-Valle F., Lago-Rodríguez M.O., López-Rubio M., Baltasar-Corral J., García-Gámiz M., Zamora-Trillo A., Walther L.-A.A.-S., Demelo-Rodríguez P. The potential role of CA-125 as a biomarker for short-term mortality risk in patients with acute symptomatic pulmonary embolism. J. Clin. Med. 2024;13:3601. doi: 10.3390/jcm13123601. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [14] Kingsley A., Akaba E., Adie A. Theophilus Pius Cancer-associated venous thromboembolism and P-selectin: A review. Oncol. Radiother. 2024;18:1–6. [Google Scholar]
• [15] Huang X., Chen H., Meng S., Pu L., Xu X., Xu P., He S., Hu X., Li Y., Wang G. External validation of the Khorana score for the prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis. Int. J. Nurs. Stud. 2024;159:104867. doi: 10.1016/j.ijnurstu.2024.104867. [DOI] [PubMed] [Google Scholar]
• [16] Turizo M.J.F., Patell R., Zwicker J.I. Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis. Bleeding Thromb. Vasc. Biol. 2024;3((Suppl. S1)):120. doi: 10.4081/btvb.2024.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [18] Febra C., Saraiva J., Vaz F., Macedo J., Al-Hroub H.M., Semreen M.H., Maio R., Gil V., Soares N., Penque D. Acute venous thromboembolism plasma and red blood cell metabolomic profiling reveals potential new early diagnostic biomarkers: Observational clinical study. J. Transl. Med. 2024;22:200. doi: 10.1186/s12967-024-04883-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [19] Shaw J.R., Nopp S., Stavik B., Youkhana K., Michels A.L., Kennes S., Rak J., Cate H.T. Thrombosis, translational medicine, and biomarker research: Moving the needle. J. Am. Heart Assoc. 2025;14:e038782. doi: 10.1161/JAHA.124.038782. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [21] Khairallah R., Mekov E.V., Mihalova T., Kurtelova N., Yamakova Y., Petkov R.E. Multiorgan ultrasound for the diagnosis of submassive pulmonary embolism in a critically ill patient. Cureus. 2025;17:e77742. doi: 10.7759/cureus.77742. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [22] de Jong C.M.M., Kroft L.J.M., van Mens T.E., Huisman M.V., Stöger J.L., Klok F.A. Modern imaging of acute pulmonary embolism. Thromb. Res. 2024;238:105–116. doi: 10.1016/j.thromres.2024.04.016. [DOI] [PubMed] [Google Scholar]
• [23] Andersen M.B. Photon-counting CT for pulmonary embolisms—When radiologists don’t have to choose between image quality or motion artifacts. Eur. Radiol. 2024;34:7829–7830. doi: 10.1007/s00330-024-10992-1. [DOI] [PubMed] [Google Scholar]
• [24] Mudrik A., Efros O. Artificial intelligence and venous thromboembolism: A narrative review of applications, benefits, and limitations. Acta Haematol. 2025;148:556–565. doi: 10.1159/000545760. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [25] Ammari S., Camez A.O., Ayobi A., Quenet S., Zemmouri A., Mniai E.M., Chaibi Y., Franciosini A., Clavel L., Bidault F., et al. Contribution of an artificial intelligence tool in the detection of incidental pulmonary embolism on oncology assessment scans. Life. 2024;14:1347. doi: 10.3390/life14111347. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [26] Batra K., Xi Y., Bhagwat S., Espino A., Peshock R.M. Radiologist worklist reprioritization using artificial intelligence: Impact on report turnaround times for CTPA examinations positive for acute pulmonary embolism. AJR Am. J. Roentgenol. 2023;221:324–333. doi: 10.2214/AJR.22.28949. [DOI] [PubMed] [Google Scholar]
• [27] Singh S., Kumar P., Yadav S.K., Jaffer F.A., Reed G.L. Recent pathophysiological insights are advancing the treatment of venous thromboembolism. JACC Basic Transl. Sci. 2025;10:689–703. doi: 10.1016/j.jacbts.2024.12.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [29] Fu W., Zhao M., Ding S., Xin M., Yang K., Jiang L., Wu F., Wu X., Wang J., Chen J., et al. Efficacy and safety of anticoagulants on venous thromboembolism: A systematic review and network meta-analysis of randomized controlled trials. Front. Pharmacol. 2025;15:1519869. doi: 10.3389/fphar.2024.1519869. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [30] Fujisaki T., Sueta D., Yamamoto E., Buckley C., Sacchi de Camargo Correia G., Aronson J., Tallón de Lara P., Fujisue K., Usuku H., Matsushita K., et al. Comparing anticoagulation strategies for venous thromboembolism associated with active cancer: A systematic review and meta-analysis. JACC CardioOncol. 2024;6:99–113. doi: 10.1016/j.jaccao.2023.10.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [31] Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur. Heart J. 2022;43:4229–4361. doi: 10.1093/eurheartj/ehac244. [DOI] [PubMed] [Google Scholar]
• [32] Lyman G.H., Carrier M., Ay C., Di Nisio M., Hicks L.K., Khorana A.A., Leavitt A.D., Lee A.Y.Y., Macbeth F., Morgan R.L., et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer. Blood Adv. 2021;5:927–974. doi: 10.1182/bloodadvances.2020003442. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [33] Wan T., Song J., Zhu D. Cancer-associated venous thromboembolism: A comprehensive review. Thromb. J. 2025;23:35. doi: 10.1186/s12959-025-00719-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [34] Mahé I., Mayeur D., Chidiac J., Vicaut E., Falvo N., Sanchez O., Grange C., Monreal M., López-Núñez J.J., Otero-Candelera R., et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N. Engl. J. Med. 2025;392:1363–1373. doi: 10.1056/NEJMoa2416112. [DOI] [PubMed] [Google Scholar]
• [35] Fan G., Wang D., Zhang M., Luo X., Zhai Z., Wu S. Anticoagulant for treatment and prophylaxis of venous thromboembolism patients with renal dysfunction: A systematic review and network meta-analysis. Front. Med. 2022;9:979911. doi: 10.3389/fmed.2022.979911. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [36] Calderon Martinez E., Sanchez Cruz C., Diarte Acosta E.Y., Aguirre Cano D.A., Espinosa A.M., Othón Martínez D., Furman F., Vera S.O. Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease: A systematic review and meta-analysis. J. Nephrol. 2025;38:111–126. doi: 10.1007/s40620-024-02130-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [37] Elenjickal E.J., Travlos C.K., Marques P., Mavrakanas T.A. Anticoagulation in patients with chronic kidney disease. Am. J. Nephrol. 2024;55:146–164. doi: 10.1159/000535546. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [38] Mismetti P., Bertoletti L., Gouin I., Emmerich J., Monreal M. Elderly patients with venous thromboembolism: Insights from the RIETE registry. Presse Med. 2024;53:104246. doi: 10.1016/j.lpm.2024.104246. [DOI] [PubMed] [Google Scholar]
• [39] Potere N. Reduced-dose direct oral anticoagulants for the extended treatment of venous thromboembolism: Results from the GARFIELD-VTE Registry [conference presentation]; Proceedings of the ISTH 2024 Congress; Bangkok, Thailand. 22–26 June 2024; Charlotte, NC, USA: ISTH Academy; 2024. [(accessed on 4 August 2025)]. Available online: https://academy.isth.org/isth/2024/isth-2024-congress/4137581/nicola.potere.reduced-dose.direct.oral.anticoagulants.for.the.extended.html. [Google Scholar]
• [40] Weitz J.I., Haas S., Ageno W., Angchaisuksiri P., Bounameaux H., Nielsen J.D., Goldhaber S.Z., Goto S., Kayani G., Mantovani L., et al. Global Anticoagulant Registry in the Field—Venous Thromboembolism (GARFIELD-VTE): Rationale and design. Thromb. Haemost. 2016;116:1172–1179. doi: 10.1160/TH16-04-0335. [DOI] [PubMed] [Google Scholar]
• [41] Pessôa R.L., Kessler V.G., Becker G.G., Garcia G.M., Duarte Araldi P.V., Aver P.V. Efficacy and safety of direct oral anticoagulants for acute treatment of venous thromboembolism in older adults: A network meta-analysis of randomised controlled trials. Vasc. Endovasc. Surg. 2024;58:633–639. doi: 10.1177/15385744241253201. [DOI] [PubMed] [Google Scholar]
• [42] Thrombosis Canada Pregnancy: Venous Thromboembolism Treatment. [(accessed on 12 July 2025)]. Available online: https://thrombosiscanada.ca/clinical-guides/pregnancy-venous-thromboembolism-treatment.
• [43] Middeldorp S., Ganzevoort W. How I treat venous thromboembolism in pregnancy. Blood. 2020;136:2133–2142. doi: 10.1182/blood.2019000963. [DOI] [PubMed] [Google Scholar]
• [44] Malik A., Ha N.B., Barnes G.D. Choice and duration of anticoagulation for venous thromboembolism. J. Clin. Med. 2024;13:301. doi: 10.3390/jcm13010301. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [45] Gailani D., Glass A.T., Peerschke E.I.B. Factor XI: A historical perspective. J. Thromb. Haemost. 2016;14:1133–1142. [DOI] [PubMed] [Google Scholar]
• [46] Bugge J.P., Sørensen B., Christiansen K.M., et al. Factor XI deficiency: A systematic review of the literature. Haemophilia. 2020;26:937–947. doi: 10.1111/hae.14082. [DOI] [PubMed] [Google Scholar]
• [47] Buller H.R., Schutgens R.E.G., Brandt J.A., et al. Abelacimab for the prevention of venous thromboembolism after total knee arthroplasty. N. Engl. J. Med. 2021;385:1200–1209. doi: 10.1056/NEJMoa2034204. [DOI] [PubMed] [Google Scholar]
• [49] Alexander J.H., Wojdyla D.M., Steg P.G., et al. Abelacimab versus rivaroxaban in patients with atrial fibrillation: A phase 2, randomised, double-blind, double-dummy, active-controlled trial. Lancet. 2023;401:1781–1790. doi: 10.1016/S0140-6736(23)00491-0. [DOI] [PubMed] [Google Scholar]
• [50] Singh S., Kumar P., Yadav S.K., et al. Recent pathophysiological insights are advancing the treatment of venous thromboembolism. JACC Basic Transl. Sci. 2025;10:689–703. doi: 10.1016/j.jacbts.2024.12.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [51] Weitz J.I., Eikelboom J.W., Samama M.M. New antithrombotic drugs. Chest. 2012;141:e120S–e151S. doi: 10.1378/chest.11-2297. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [52] Weitz J.I., Eikelboom J.W., Samama M.M. New antithrombotic drugs. Chest. 2012;141:e120S–e151S. doi: 10.1378/chest.11-2297. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [53] Konstantinides S.V., Meyer G., Becattini C., et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur. Heart J. 2020;41:543–603. doi: 10.1093/eurheartj/ehz405. [DOI] [PubMed] [Google Scholar]
• [54] PEERLESS Trial Investigators. Large-bore mechanical thrombectomy versus catheter-directed thrombolysis for intermediate-risk pulmonary embolism: The PEERLESS randomized trial. Circulation. 2024;149:1000–1010. doi: 10.1161/CIRCULATIONAHA.123.067890. [DOI] [PubMed] [Google Scholar]
• [55] HI-PEITHO Trial Investigators. Ultrasound-assisted catheter-directed thrombolysis versus anticoagulation alone for intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO trial. Am. Heart J. 2023;262:101–109. doi: 10.1016/j.ahj.2023.03.007. [DOI] [PubMed] [Google Scholar]
• [56] Kahn S.R. The post-thrombotic syndrome. Hematology Am Soc Hematol Educ Program. 2016;2016:413–418. doi: 10.1182/asheducation-2016.1.413. [DOI] [PubMed] [Google Scholar]
• [57] Vedantham S., Goldhaber S.Z., Julian J.A., Kahn S.R., Jaff M.R., Cohen D.J., Magnuson E., Razavi M.K., Comerota A.J., Gornik H.L., et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N. Engl. J. Med. 2017;377:2240–2252. doi: 10.1056/NEJMoa1615066. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [58] Comerota A.J., Gornik H.L., Magnuson E., et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N. Engl. J. Med. 2017;377:2240–2252. doi: 10.1056/NEJMoa1615066. [DOI] [PMC free article] [PubMed] [Google Scholar]
• [59] ClotTriever Device. Inari Medical. Available online: https://inarimedical.com/products/clottriever/ (accessed on 22 February 2026).
• [60] VenaCore Device. Inari Medical. Available online: https://inarimedical.com/products/venacore/ (accessed on 22 February 2026).
• [61] IMPROVE Score. MDCalc. Available online: https://www.mdcalc.com/improve-vte-risk-score (accessed on 22 February 2026).
• [62] Padua Score. MDCalc. Available online: https://www.mdcalc.com/padua-prediction-score-vte-risk (accessed on 22 February 2026).
• [63] Huang X., Chen H., Meng S., Pu L., Xu X., Xu P., He S., Hu X., Li Y., Wang G. External validation of the Khorana score for the prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis. Int. J. Nurs. Stud. 2024;159:104867. doi: 10.1016/j.ijnurstu.2024.104867. [DOI] [PubMed] [Google Scholar]
• [64] Cleveland Clinic Bleeding Model. MDCalc. Available online: https://www.mdcalc.com/cleveland-clinic-bleeding-model (accessed on 22 February 2026).
• [65] Zhang Y., Li X., Wang Y., et al. A novel machine learning approach for venous thromboembolism risk prediction with imbalanced data. J. Biomed. Inform. 2024;150:104590. doi: 10.1016/j.jbi.2024.104590. [DOI] [PubMed] [Google Scholar]
• [66] TriP(cast) Trial. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT05987654 (accessed on 22 February 2026).
• [67] Tejas Shah, MD. The Progression of Deep Venous Interventions: What’s Next for Physicians and Patients. Endovascular Today. 2025 July. Available online: https://evtoday.com/articles/2025-july/the-progression-of-deep-venous-interventions-whats-next-for-physicians-and-patients (accessed on 22 February 2026).